-The Times of India NEW DELHI: Mangal Singh's three sons were forced to work as daily wage labourers in Gujarat, hundreds of kilometres from their village in Rajasthan's Ajmer district, before the National Rural Employment Guarantee Act (NREGA) was introduced. They were employed there for perilous digging of wells and stayed away from their home for months leaving their 82-year-old father to fend for himself. The NREGA came as a big boon for...

-The Indian Express New Delhi: "This government is trying to snatch away our Rights, of both employment and land. We have come all the way to fight such injustice. Several people in my village voted for this government hoping they would improve our lives but they are doing just the opposite," said Lal Singh from Rajsamand district in Rajasthan. At a time when the NDA government's proposals to bring changes to some...

-The Hindu The clean-up of the plant is pending due to legal disputes Thirty years after India's worst industrial disaster in Bhopal, contamination owing to the leakage of poisonous gas from the Union Carbide pesticide factory continues to affect residents. The leak of 40 tonnes of methyl isocyanate on the intervening night of December 2 and 3, 1984, killed thousands of people in its immediate aftermath and continued to kill people in the...

-The Hindu Business Line Questioning the kind of growth model pursued by the Government, civil society activists on Saturday called for a wider public debate on the reported move to curtail social sector spending on schemes such as the rural job guarantee scheme, MGNREGA, and for the HIV affected. "Considering the fact that the Government is forecasting a 5.3 per cent growth rate for this year, the social sector cuts in Budget...

-The Times of India MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly Rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law. Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm Novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV,...